Enfermedad Residual Mínima en el Cáncer de Mama: Interacciones del Microambiente Tumoral, Métodos de Detección y...

Breast cancer is the most common cancer in women, depending on the sub-type of breast cancer treatment options are different. After completing adjuvant therapy, there are patients who may relapse even many years later. This review examines minimal residual disease, defined as small, microscopic foci of cancer cells that have survived curative treatment, have disseminated to distant tissues, and implanted there. However, the cancer cells do not exist alone but are a small part of the tumour microenvironment, described as an ecosystem. This includes stromal cells, immunosuppressive regulatory T-cells, myeloid derived suppression cells, cancer associated fibroblasts, tumour associated macrophages. The balance of the immunosuppressive tumour microenvironment and the anti-tumour immune response will determine if there is a future relapse. The interactions between the cancer cells and the tumour microenvironment are dynamic and change with time. Most therapeutic options involve therapies directed against tumour cells, only in the last few years has there been attention on the dynamic effects of the tumour microenvironment and the cancer cells on disease progression and the possibility of decreasing the risk of metastatic disease. This article reviews the latest development in preventing metastatic disease by influencing the tumour microenvironment; at best eliminating cancer cells or at least prolonging the latent period of cancer cell dormancy.